Oasmia Pharmaceutical AB Finance Income Cost
Oasmia Pharmaceutical AB reported Finance Income Cost of -SEK 14.29 million for the 12-month period ending 2018-04-30, per its 20-F filed 2018-09-14.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceIncomeCost · last filed 2018-09-14
| Period end | Finance Income Cost 12 month |
|---|---|
| 2018-04-30 | -14.29M SEK 20-F · filed 2018-09-14 |
| 2017-04-30 | -19.76M SEK 20-F · filed 2018-09-14 |
| 2016-04-30 | -8.85M SEK 20-F · filed 2018-09-14 |